Video

Dr. Riedel Discusses the Rarity of Uterine Sarcomas

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the rarity and characteristics of uterine sarcomas.

Richard F. Riedel, MD, associate professor of medicine, Duke Cancer Institute, discusses the rarity and characteristics of uterine sarcomas.

The presentations of the disease are varied, but one of the most common symptoms is abnormal bleeding, or what is known as menorrhagia. Riedel says this could result in an evaluation and the detection of a mass. Oftentimes, uterine sarcomas can be misdiagnosed as a uterine fibroid. It is not until the mass is removed that the cancer is actually identified.

The biggest challenge lies in the rarity of the disease. Sarcomas as a whole represent about 1% of cancers in adults, and uterine sarcomas represent about 5% of all uterine cancers. Essentially, 99% of the time, a uterine mass will be benign as opposed to sarcoma, which Riedel says can mislead physicians at times. The symptoms are also sometimes nonspecific.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD